This site is intended for health professionals only

Pfizer announces 70% fall in profit

teaser

Pfizer has announced a steep fall in fourth-quarter profits, but claims it is well positioned to see growth during 2008.

Net income for the three months to 31 December fell 70% to $2.88bn, compared with $9.45bn for the same period the year before.

The company, which is the world’s largest pharmaceutical firm, added that revenue climbed 4% to $13.07bn from $12.60bn, as international sales helped offset the loss of patent protection on its blood pressure drug Norvasc (amlodipine besylate), and antidepressant Zoloft (sertraline).

Sales of its anticholesterol drug Lipitor (atorvastatin) increased by 3% to $3.4bn as the weaker dollar negated a slowdown in US sales.

CEO Jeff Kindler said: “We are executing against a broad plan to position Pfizer to deliver long-term value.

Article continues below this sponsored advert
Featured Image
Explore the latest advances in cardiovascular care delivered by renowned experts from recognised Centres of Excellence and other NHS trusts around the UK. Gain CPD, put your burning questions to the experts, and boost your confidence when it comes to care for your patients.
Advertisement

“Our new products – Lyrica (pregabalin), Chantix (varenicline), and Sutent (sunitinib) – are performing well. We are continuing to strengthen our senior leadership team and enhance accountability.

“We are shifting investments into high-priority therapeutic areas, revamping our R&D operations and acquiring new compounds and technologies that we believe are especially promising. These actions taken together have made Pfizer a stronger company than it was a year ago, and we look forward to continued progress in 2008.”

Copyright © PA Business 2008

Pfizer

Take part in our prize-draw survey






Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine

x